

Differential expression of long non-coding RNAs in bleomycin-induced lung fibrosis

GUOHONG CAO^{1,2}, JINJIN ZHANG¹, MEIRONG WANG¹, XIAODONG SONG¹,
WENBO LIU¹, CUIPING MAO¹ and CHANGJUN LV^{1,2}

¹Medicine Research Center, Binzhou Medical University, Yantai, Shandong 264003;

²Department of Respiratory Medicine, Affiliated Hospital to Binzhou Medical University, Binzhou, Shandong 256602, P.R. China

Received February 21, 2013; Accepted April 29, 2013

DOI: 10.3892/ijmm.2013.1404

Abstract. Recent studies suggest that long non-coding RNAs (lncRNAs) are more involved in human diseases than previously realized. A growing body of evidence links lncRNA mutation and dysregulation to diverse human diseases. However, the association of lncRNAs with the pathogenesis of lung fibrosis remains poorly understood. In this study, we detected changes in hydroxyproline and collagen levels, as well as the ultrastructure of lung tissue to develop a rat model of lung fibrosis. The differentially expressed lncRNAs and mRNA profiles between fibrotic lung and normal lung tissue were analyzed using microarrays. Gene Ontology analysis and pathway analysis were performed for further research. Two differentially expressed lncRNAs, namely, AJ005396 and S69206, were detected by *in situ* hybridization to validate the microarray data. The results revealed that the number of collagen fibers in the interstitial lung tissue significantly increased in the model group compared with the normal group. In total, 210 and 358 lncRNAs were upregulated and downregulated, respectively, along with 415 upregulated and 530 downregulated mRNAs in the rats with lung fibrosis. AJ005396 and S69206 were upregulated in the fibrotic lung tissue, consistent with the microarray data, and

were located in the cytoplasm of the interstitial lung cells. In conclusion, the expression profile of the lncRNAs was significantly altered in the fibrotic lung tissue and these transcripts are potential molecular targets for inhibiting the development of lung fibrosis.

Introduction

Idiopathic pulmonary fibrosis (IPF) is a common, chronic, progressive and usually lethal fibrotic lung disease with poor prognosis (1). This disease is characterized by focal areas of alveolar epithelial cell injury and the excessive proliferation of mesenchymal cells in the interstitium, which results in the excessive deposition of extracellular matrix (ECM) and distorted architecture leading to impaired gas exchange (2,3). Although many pathobiological concepts are emerging, including the role of aging and cellular senescence, oxidative stress, endoplasmic reticulum stress, cellular plasticity, microRNA (miRNA) and mechanotransduction, the molecular mechanisms behind IPF are not yet completely understood (4).

The Encyclopedia of DNA Elements (ENCODE) project, which aimed to comprehensively characterize the human genome, has shown that >90% of the genome has been transcribed; however, only 1-2% of that is composed of genes (5). The majority of these transcripts are not translated into proteins and are, therefore, termed non-coding RNAs (ncRNAs).

Long non-coding RNAs (lncRNAs), a type of ncRNA, vary in size from 200 bp to >100 kb, and are transcribed by RNA polymerase II (6). They play an important role in imprinting (7), enhancing various biological functions (8), X chromosome inactivation (9), chromatin structure (10) and genomic rearrangement during the generation of antibody diversity (11). Thus, lncRNAs are critical for normal development and, in many cases, are deregulated in diseases, such as cancer (12).

Thus far, studies on lncRNAs in IPF are limited. Studies on differentially expressed lncRNAs are necessary for the classification of genes regulated by lncRNAs in IPF. Among the lncRNA profiling technologies, lncRNA microarrays offer a new tool for understanding the biological role of lncRNAs. This study aimed to construct lncRNA expression profiles in

Correspondence to: Professor Xiaodong Song or Dr Changjun Lv, Medicine Research Center, Binzhou Medical University, No. 346 Guanhai Road, Laishan, Yantai, Shandong 264003, P.R. China
E-mail: songxd71@yahoo.com.cn
E-mail: love61sky@yahoo.com.cn

Abbreviations: lncRNA, long non-coding RNA; IPF, idiopathic pulmonary fibrosis; ECM, extracellular matrix; TEM, transmission electron microscope; IGF, insulin-like growth factor; RMRP, RNA component of mitochondrial RNA processing endoribonuclease; TERC, telomerase RNA component; TERT, telomerase reverse transcriptase; RMCP-1, rat mast cell protease 1 precursor

Key words: lung fibrosis, long non-coding RNA, microarray, AJ005396, S69206

bleomycin-induced lung fibrosis and normal lung tissue, in order to identify the differentially expressed lncRNAs and to discover new molecular targets for the therapy of IPF.

Materials and methods

Animals. Sprague Dawley (SD) rats (8 to 12 weeks old) were provided by the Yantai Green Leaf Experimental Animal Center, Yantai, China. A total of 20 SD rats were randomly divided into 2 groups ($n=10$ in each group): the normal control and lung fibrosis model group. All animal experiments were carried out in accordance with the principles of the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

Bleomycin administration. Rats in the model group were administered 5 mg/kg bleomycin (Daiichi Pure Chemicals Co., Ltd., Tokyo, Japan) dissolved in sterile phosphate-buffered saline (PBS) via a single intratracheal instillation under anesthesia. The normal control rats were administered an equal volume of saline. Lung tissues were harvested on the 28th day following treatment with bleomycin.

Hydroxyproline assay. The total collagen content in the lungs was measured using a colorimetric assay. The lung specimens were washed with normal saline and hydrolysed with 6 ml/l hydrochloric acid at 100°C for 5 h. The hydrolysates were then diluted with distilled water after neutralizing with sodium hydroxide. The hydroxyproline level in the hydrolysates was then assessed colorimetrically at 560 nm with *p*-dimethyl-aminobenzaldehyde, and the results were calculated as mg hydroxyproline/g.

Masson's trichrome. Masson's trichrome method was used to show collagen deposition. After fixing with 4% paraformaldehyde overnight, dehydration in 70% ethanol and clearing in xylene, the lung tissues were embedded in paraffin wax. Sections (4 μ m) were prepared and stained with Masson's trichrome. Nine random areas were examined at a magnification of $\times 400$. The severity of fibrosis was blindly determined by a semiquantitative assay.

Observation of cell morphology under a transmission electron microscope (TEM). Lung tissues were fixed in fresh 3% glutaraldehyde for at least 4 h at 4°C, post-fixed in 1% osmium tetroxide for 1.5 h, dehydrated in a gradient series of ethanol, infiltrated with Epon 812, embedded and cultured at 37, 45 and 60°C for 24 h. Ultrathin sections were ultracut using an ultracut E ultramicrotome and stained with uranyl acetate and lead citrate prior to observation under a JEM-1400 TEM (Jeol Ltd., Tokyo, Japan).

RNA isolation and quality assessment. Total RNA from lung tissues was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and the RNeasy mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. RNA quantity and quality were measured using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Inc., Wilmington, DE, USA) and RNA integrity was assessed by standard denaturing agarose gel electrophoresis.

lncRNA microarray. ArrayStar, Inc. (Rockville, MD, USA) rat lncRNA microarray was used and run by the service provider. The rat lncRNA array was designed for profiling the lncRNAs and protein-coding genes. Approximately 9,000 rat lncRNA candidates were identified from the most authoritative databases, such as NCBI RefSeq, UCSC all_mrna records and orthologs of mouse lncRNAs. Highly similar sequences and ncRNAs shorter than 200 bp were excluded. Probes for housekeeping genes and negative probes were printed multiple times to ensure hybridization quality. ArrayStar designed the lncRNA ChIP, taking into account not only the transcript already in the database, but also with the aim of predicting new transcripts. 'Potential lncRNA' is a probe designed to help researchers discover new lncRNAs and explore their functions.

RNA labeling and array hybridization. Sample labeling and array hybridization were performed according to the Agilent One-Color Microarray-Based Gene Expression Analysis protocol (Agilent Technologies, Inc., Santa Clara, CA, USA). Briefly, 1 μ g of total RNA from each sample was linearly amplified and labeled with Cy3-dCTP. The labeled cRNAs were purified using the RNeasy mini kit (Qiagen). The concentration and specific activity of the labeled cRNAs (pmol Cy3/ μ g cRNA) were measured using the NanoDrop ND-1000 spectrophotometer. A total of 1 μ g of each labeled cRNA was fragmented by the addition of 11 μ l 10X blocking agent and 2.2 μ l of 25X fragmentation buffer, then the mixture was heated at 60°C for 30 min; finally, 55 μ l 2X GE hybridization buffer were added to dilute the labeled cRNA. Hybridization solution (100 μ l) was dispensed into the gasket slide and assembled to the lncRNA expression microarray slide. The slides were incubated for 17 h at 65°C in an Agilent hybridization oven. The hybridized arrays were washed, fixed and scanned using the Agilent DNA Microarray Scanner.

Microarray data analysis. Agilent Feature Extraction software (version 10.7.3.1) was used to analyze the acquired array images. Quantile normalization and subsequent data processing were performed using the GeneSpring GX v11.5.1 software package (Agilent Technologies, Inc.). Following quantile normalization of the raw data, lncRNAs and mRNAs with at least 2 out of 2 present or marginal flags were selected for further data analysis. Differentially expressed lncRNAs and mRNAs were identified through fold change filtering. Hierarchical clustering was performed using the Agilent GeneSpring GX software (version 11.5.1). Gene Ontology (GO) analysis and pathway analysis were performed using the standard enrichment computation method.

In situ hybridization. The fixed lung tissues were dehydrated in ethanol, cleared in xylene, transferred to paraffin and sectioned at 5 μ m. Paraffin sections were treated with Triton X-100 to enhance probe penetration following conventional dewaxing with water. The slides were washed in PBS and fixed again in 4% paraformaldehyde. After washing in PBS and pre-hybridization for 4 h at 40°C, the slides were hybridized with digoxin-labeled RNA oligonucleotide probes at 40°C overnight. The following day, the lung tissue sections were washed with various concentrations of saline sodium citrate (SSC) at 50°C. After the addition of blocking solution




Figure 1. Detection of bleomycin-induced lung fibrosis. (A) The normal interstitial lung tissue under a transmission electron microscope (TEM). The morphology and structure of the alveolar epithelial cell was integrated. The width of lung interval was normal and contained a small amount of collagen fibers. (B) The interstitial lung tissue contained large amounts of collagen and collagen fibers in the model group as shown under a TEM. (C) The normal blood barrier under a TEM. The structure of the blood barrier was completed and the basement membrane was normal. (D) The blood barrier was damaged in the model group under a TEM. (E) The normal lung tissue observed by Masson's trichrome staining. Collagen were displayed as blue in interstitial lung. (F) Significantly increased collagen fibers in the model group observed by Masson's trichrome staining. (G) Integrated optical density (IOD) analysis of collagen levels. (H) Analysis of hydroxyproline content in the lung tissue. Hydroxyproline levels were increased in the model group. *Statistically significant difference at $P < 0.05$.

made with sheep serum for 1 h at 37°C, the slides were incubated with anti-digoxigenin-AP antibody (Roche Diagnostics GmbH, Mannheim, Germany) overnight at 4°C. Finally, the slides were stained with NBT/BCIP solution (Roche Diagnostics GmbH) avoiding light after being washed with Tris-NaCl buffer. The RNA oligonucleotide probe of AJ005396 was as follows: AATGTCCTTTGGAGGAAGGAGATATGAATTTTATCAATAAATCAAGTCTTGTCTA CCTGG. The RNA oligonucleotide probe of S69206 was as follows: TGCACGAGTCAGAGTCTCCAAGCTAGAGAA CTCTT TTGATATCCCTTGGGATCAACAAG.

Statistical analysis. All data are expressed as the means \pm SD. Statistical analysis was performed using SPSS11.0 software by one-way ANOVA. A P-value < 0.05 was considered to indicate a statistically significant difference.

Results

Detection of bleomycin-induced lung fibrosis. As the hydroxyproline content can indirectly reflect collagen content, we determined the levels of hydroxyproline to evaluate the degree of fibrosis. The hydroxyproline content in the lungs was significantly increased in the model group compared with the normal group (Fig. 1H). We also used Masson's trichrome staining and TEM to observe histopathological changes and collagen deposition following bleomycin infusion. The results revealed a clear pulmonary structure with an integral air-blood barrier and lower collagen levels in the normal group (Fig. 1A, C and E). By contrast, the structure of the lung tissue was disordered, the air-blood barrier was severely damaged, the pulmonary interalveolar septum was thickened and a significant number of collagen fibers were deposited in the model group (Fig. 1B, D, F and G). These results indicated that we successfully established a model of bleomycin-induced lung fibrosis.

RNA quality control (QC). The integrity of the RNA was assessed by electrophoresis on a denaturing agarose gel. The RNA run on the denaturing gel had sharp 28S and 18S rRNA bands. The 28S rRNA band was approximately twice as intense as the 18S rRNA band. This 2:1 intensity ratio indicated that the RNA was intact. A NanoDrop ND-1000 spectrophotometer was then used to accurately measure the RNA concentrations (OD_{260}), protein contamination (ratio of OD_{260}/OD_{280}) and organic compound contamination (ratio of OD_{260}/OD_{230}). The $OD_{A_{260}}/A_{280}$ ratio was close to 2.0. The $OD_{A_{260}}/A_{230}$ ratio was calculated as > 1.8 .

Differentially expressed lncRNAs and mRNAs. To examine the potential biological functions of lncRNAs in lung fibrosis, we determined the lncRNA and mRNA expression profiles in bleomycin-induced lung fibrosis through microarray analysis (Fig. 2). Up to 568 lncRNAs were differentially expressed in the bleomycin-treated lung samples compared with the normal control group, among which 210 were upregulated, whereas 358 were downregulated. A total of 945 mRNAs were differentially expressed. Among these mRNAs, 415 were upregulated, whereas 530 were downregulated. The fold change threshold was ≥ 2.0 . The list only shows the partial results for the differentially expressed lncRNAs (Table I) and mRNAs (Table II) in the model vs. the normal control groups.

Location and expression of AJ005396 and S69206. To validate the microarray data and to explore the location of lncRNAs, 2 of the upregulated lncRNAs (AJ005396 and S69206) selected by the fold change and the raw intensities (Table IA) were analyzed by ISH. A blue-violet color indicated a positive reaction. The results revealed that the alveoli have clear hollow cavities, and that the alveolar membranes were thinner in the normal group compared to the model group. AJ005396 and S69206 were observed in the cytoplasm of the interstitial lung cells. Their expression was significantly increased in the




Figure 2. lncRNA and mRNA profile comparison between the fibrotic lung sample and the normal sample. (A) The scatter-plot was used for assessing the lncRNA and (B) mRNA expression variation between the model and normal lung sample. The values of x-axis and y-axis in the scatter-plot were the normalized signal values of each sample (\log_2 scaled). The green lines are fold change lines (the default fold change value given is 2.0). The lncRNAs above the top green line and below the bottom green line indicated >2.0 -fold change in expression of lncRNAs between the 2 compared samples. (C) The hierarchical clustering of all targets value lncRNAs and (D) mRNA showed a distinguishable lncRNA and mRNA expression profiling among samples. 'Red' indicates high relative expression, and 'blue' indicates low relative expression.

model group compared with the normal control group which was consistent with our microarray data (Fig. 3).

Pathway analysis. Pathway analysis was carried out based on the latest Kyoto Encyclopedia of Genes and Genomes (KEGG) database (13). This analysis was used to determine the biological pathways associated with the most differentially expressed mRNAs in lung fibrosis. Up to 22 downregulated and 16 upregulated pathways were identified associated with




Figure 3. Location and expression of lncRNAs by *in situ* hybridization. (A) Location and expression of AJ005396. AJ005396 is stained blue in the plasma of interstitial lung cells. (A-1) Normal group. Images were captured at a magnification of x100, and inset images (A-2) were captured at a magnification of x400. (A-3) Model group. Images were captured at a magnification of x100, and inset images (A-4) were captured at a magnification of x400. (A-5) Integrated optical density (IOD) analysis of AJ005396. AJ005396 was upregulated in the model group, consistent with the ChIP results. (B) Location and expression of S69206. S69206 is stained blue in the plasma of interstitial lung cells. (B-1) Normal group. Images were captured at a magnification of x100, and inset images (B-2) were captured at a magnification of x400. (B-3) Model group. Images were captured at a magnification of x100, and inset images (B-4) were captured at a magnification of x400. (B-5) IOD analysis of S69206. S69206 was upregulated in model group and consistent with the chip results. **Statistically significant difference at $P < 0.01$.

cytokine-cytokine receptor interaction, chemokine signaling pathway, cell adhesion molecules, Jak/STAT signaling pathway, cell cycle, complement and coagulation cascades, the peroxisome proliferator-activated receptor (PPAR) signaling

Table I. Screening of differentially expressed lncRNAs.

A, Upregulated lncRNAs

SeqID	Fold change	Log fold change	Absolute fold change	Regulation	Model (raw)	Normal (raw)	Model (normalized)	Normal (normalized)
S69206	210.7381700	7.719308	210.73817	Up	3141.4421	18.151241	11.734264	4.0149565
MRAK053938	7.0106416	2.8095465	7.0106416	Up	946.3922	172.075	10.021786	7.2122393
AJ005396	6.756214	2.756215	6.756214	Up	2243.4438	409.89282	11.255636	8.499421
MRAK143591	5.094425	2.3489194	5.094425	Up	132.47684	33.959503	7.2617292	4.91281
BC091243	4.1729445	2.0610657	4.1729445	Up	4966.646	1405.8405	12.391487	10.330421
MRAK081523	4.068016	2.0243254	4.068016	Up	349.46616	114.143684	8.62955	6.6052246
MRAK158582	3.3001428	1.7225285	3.3001428	Up	52.645744	20.9094	5.929387	4.2068586
AY007370	3.1992314	1.6777253	3.1992314	Up	159.31357	66.472755	7.5263243	5.848599
XR_008064	3.097738	1.6312151	3.097738	Up	56.149826	23.58112	6.0165567	4.3853416
MRuc007mlw	2.9334714	1.552609	2.9334714	Up	84.11148	37.512997	6.623669	5.07106
M77361	2.8096433	1.490387	2.8096433	Up	43.492096	20.006016	5.639081	4.148694
MRAK089766	2.0438807	1.031311	2.0438807	Up	24.99775	15.457541	4.81422	3.782909
MRAK029230	2.6328747	1.3966389	2.6328747	Up	60.88167	30.110182	6.138603	4.7419643
MRAK045258	2.0882866	1.0623198	2.0882866	Up	32.666325	19.7309	5.194111	4.131791
XR_007265	3.2810228	1.7141457	3.2810228	Up	14708.692	5233.981	13.952381	12.238235
uc.161+	2.5087821	1.3269873	2.5087821	Up	116.44161	61.64021	7.0759335	5.748946
BC166600	2.0669036	1.047471	2.0669036	Up	47.62331	29.747671	5.7733784	4.7259073
AM293774	2.5931861	1.3747258	2.5931861	Up	299.42767	151.79784	8.409706	7.0349803
Z93366	3.409905	1.7697315	3.409905	Up	163.78604	63.930973	7.566777	5.7970457
XR_007062	2.5269985	1.3374248	2.5269985	Up	100.54225	53.123276	6.8767934	5.5393686

B, Downregulated lncRNAs

SeqID	Fold change	Log fold change	Absolute fold change	Regulation	Model (raw)	Normal (raw)	Model (normalized)	Normal (normalized)
XR_005532	-20.369864	-4.3483644	20.369864	Down	22.40888	577.1471	4.6590877	9.007452
AF159100	-12.764141	-3.6740246	12.764141	Down	311.6397	4852.019	8.463682	12.137707
MRAK018459	-6.187315	-2.6293135	6.187315	Down	62.63327	504.11053	6.1816454	8.810959
MRAK153573	-5.0353293	-2.332086	5.0353293	Down	58.95229	389.28036	6.090506	8.422592
MRAK040987	-4.682474	-2.227271	4.682474	Down	68.1992	422.10565	6.3133345	8.540606
MRAK033233	-4.4625397	-2.157865	4.4625397	Down	45.224556	266.30106	5.6959915	7.8538566
MRuc008euj	-4.306261	-2.1064358	4.306261	Down	48.580467	275.86755	5.8036256	7.9100614
BC088752	-3.3241138	-1.7329698	3.3241138	Down	44.798225	197.15247	5.683831	7.416801
AF352172	-3.1898289	-1.6734791	3.1898289	Down	30.87954	128.38947	5.107747	6.781226
MRAK036098	-3.0710256	-1.6187205	3.0710256	Down	23.849337	96.428856	4.751513	6.3702335
AB072248	-2.826814	-1.499177	2.826814	Down	95.15817	356.84283	6.7976427	8.29682
MRAK031681	-2.5653043	-1.3591299	2.5653043	Down	184.00778	610.2933	7.723872	9.083002
XR_007761	-2.4044764	-1.2657228	2.4044764	Down	84.096306	272.36227	6.623521	7.8892436
MRAK081707	-2.5626018	-1.3576093	2.5626018	Down	27.748964	93.19641	4.9642982	6.3219075
MRAK134949	-2.3397248	-1.2263389	2.3397248	Down	15.463284	46.174065	4.121881	5.34822
MRAK080342	-2.2991571	-1.2011051	2.2991571	Down	1250.1749	3400.0752	10.417191	11.618296
MRuc007wwx	-2.3716562	-1.2458949	2.3716562	Down	216.22974	656.4996	7.94957	9.195465
MRAK042040	-2.2730455	-1.1846266	2.2730455	Down	94.70941	288.2609	6.7916226	7.976249
XR_007395	-2.0279934	-1.0200529	2.0279934	Down	632.9264	1555.753	9.455593	10.475646
MRAK042427	-2.4156244	-1.2723961	2.4156244	Down	475.61267	1413.5208	9.065523	10.337919

To identify differentially expressed lncRNAs, we performed a fold change filtering between the 2 samples. The threshold is a fold change ≥ 2.0 . SeqID, lncRNA name. Absolute fold change, absolute fold change between the 2 samples. Regulation, 'up' indicates upregulation; 'down' indicates downregulation. Model-normal (raw), raw intensities of each sample. Model - normal (raw), raw intensities of each sample. Model - normal (normalized), normalized intensities of each sample (log₂ transformed). The list only shows part of the results of lncRNAs with an up- or down-regulation in expression in the model vs. the normal group.

Table II. Screening of differentially expressed mRNAs.

A, Upregulated mRNAs								
SeqID	Fold change	Log fold change	Absolute fold change	Regulation	Model (raw)	Normal (raw)	Model (normalized)	Normal (normalized)
NM_019322	84.40361	6.399233	84.40361	Up	3035.9275	44.22444	11.6874275	5.2881947
NM_053605	19.508001	4.285994	19.508001	Up	967.8983	62.61611	10.053534	5.7675395
NM_031808	11.300015	3.4982529	11.300015	Up	314.0429	35.48023	8.475712	4.977459
NM_001024763	8.801827	3.137803	8.801827	Up	281.56186	40.555855	8.315399	5.177596
NM_001113781	8.117821	3.0210924	8.117821	Up	481.5752	76.96868	9.081482	6.0603895
NM_134329	7.2603674	2.8600426	7.2603674	Up	418.20984	74.544266	8.874704	6.014662
NM_053750	6.7114744	2.7466297	6.7114744	Up	208.96045	40.024292	7.9063206	5.159691
NM_001009919	5.0369353	2.3325462	5.0369353	Up	207.11671	54.101795	7.8946905	5.5621443
NM_031073	4.622809	2.2087698	4.622809	Up	445.40768	126.902695	8.972042	6.7632723
NM_145093	4.364931	2.125959	4.364931	Up	384.9827	115.6088	8.749628	6.623669
NM_012845	4.2602963	2.0909538	4.2602963	Up	261.5588	80.66606	8.215511	6.1245575
NM_001106425	4.04188	2.0150266	4.04188	Up	189.40274	61.544144	7.761023	5.7459965
B, Downregulated mRNAs								
SeqID	Fold change	Log fold change	Absolute fold change	Regulation	Model (raw)	Normal (raw)	Model (normalized)	Normal (normalized)
NM_012589	-28.815973	-4.848797	28.815973	Down	132.6186	4777.8477	7.264641	12.113438
NM_053624	-11.540494	-3.528633	11.540494	Down	28.109798	413.18723	4.983698	8.512331
NM_001013145	-10.523788	-3.3955822	10.523788	Down	47.613003	643.6955	5.773218	9.1688
NM_001024890	-7.6730404	-2.9397984	7.6730404	Down	43.61209	434.4988	5.6424265	8.582225
NM_001109233	-7.4248977	-2.8923712	7.4248977	Down	24.390635	235.72002	4.7840214	7.6763926
NM_022280	-6.217645	-2.6363683	6.217645	Down	43.506603	351.66534	5.639379	8.275747
NM_017226	-5.3901715	-2.4303312	5.3901715	Down	103.21507	721.87415	6.9101744	9.340506
NM_001108195	-5.0052595	-2.3234448	5.0052595	Down	44.6552	294.27753	5.6805167	8.003962
NM_001107444	-4.81651	-2.2679882	4.81651	Down	57.48932	360.80945	6.049778	8.317766
NM_133288	-4.4379377	-2.1498895	4.4379377	Down	40.90932	238.50754	5.5452423	7.695132
NM_001042354	-4.3010206	-2.104679	4.3010206	Down	81.92266	465.0587	6.5834494	8.688128
NM_201420	-4.1225066	-2.043522	4.1225066	Down	81.31964	443.837	6.572609	8.616131

To identify differentially expressed mRNAs, we performed a fold change filtering between the 2 samples. The threshold is a fold change ≥ 2.0 . SeqID, mRNA name. Absolute fold change, absolute fold change between the 2 samples. Regulation, 'up' indicates upregulation; 'down' indicates downregulation. Model - normal (raw), raw intensities of each sample. Model - normal (normalized), normalized intensities of each sample (\log_2 transformed). The list only show part of the results of lncRNAs with an up- or downregulation in expression in the model vs. the normal group.

pathway, as well as others. The predominant pathways are summarized in Fig. 4.

GO analysis. GO analysis is a functional analysis that associates differentially expressed mRNAs. The GO categories were derived from the Gene Ontology website (www.geneontology.org) and comprised of 3 structured networks: biological processes, cellular components and molecular function. According to the GO annotation tool, the differentially expressed genes were principally enriched for GO terms related to immune response, cell differentiation, tyrosine phosphorylation of STAT3 protein linked with biological processes associated with extracellular structure organiza-

tion, ECM, cytoskeleton, fibrillar collagen involved in cellular components, as well as chemokine activity, chemokine receptor binding, immunoglobulin binding and insulin-like growth factor (IGF) binding in molecular functions. The chart shows the top 10 counts of the significant enrichment terms with the most number of differentially expressed genes (Fig. 5).

Discussion

lncRNAs participate in a wide range of biological processes. Almost every step in the life cycle of genes from transcription to mRNA splicing, RNA decay and translation, is influenced by lncRNAs (14-16). Previous studies have demonstrated that




Figure 4. KEGG pathway analysis. The figure shows the top 10 counts of the predominant pathways. (A) Downregulation in model vs. normal group. (B) Upregulation in model vs. normal group. DE, differentially expressed.

the abnormal expression of lncRNAs contributes to numerous diseases (17-21). However, the profile and the biological function of lncRNAs in lung fibrosis remain unknown. In the present study, we provide new information as to the expression of lncRNAs using a rat model of bleomycin-induced lung fibrosis. To explore the role of lncRNAs in lung fibrosis, a microarray analysis was used to verify the lncRNA expression profiles. Furthermore, we selected 2 lncRNAs, AJ005396 and S69206, to validate the microarray data and explore their location for further research.

lncRNAs can be roughly classified according to the positional relationship of the protein-coding genes in the chromosome. In a recent study, Sui *et al* divided lncRNAs into 4 groups by analyzing complex transcriptional loci that include lncRNAs and their associated protein-coding genes, namely, cis-antisense lncRNAs, intronic lncRNAs, promoter-associated lncRNAs, and bidirectional lncRNAs (22). According to our microarray results, lncRNAs can also be partially subjected to a similar classification system: MRAK089766, MRAK029230 and MRAK081707, among others, belong to the sense_exon_overlap (the exon of the lncRNA overlaps with a coding transcript exon on the same genomic strand); MRAK045258, MRAK134949 and MRAK080342, among others, represent the sense_intron_overlap (the lncRNA overlaps with the intron of a coding transcript on the same genomic strand); XR_007265, MRuc007wwx and MRAK042040 are categorized under the antisense_exon_overlap (the lncRNA is transcribed from the antisense strand and overlaps with a coding transcript); uc.161+ and XR_007395 comprise the antisense_intron_overlap (the lncRNA is transcribed from the antisense strand without sharing overlapping exons); BC166600 and MRAK042427 are bidirectional (the lncRNA is oriented head to head to a coding transcript within 1,000 bp);

and AM293774, Z93366 and XR_007062, among others, are intergenic (there are no coding transcripts within 30 kb of the lncRNA) (Table I).

Although research on lncRNAs has gradually increased, only a few lncRNAs have official names and clear functions. In our microarray results, a vast majority of the differentially expressed lncRNAs in bleomycin-induced lung fibrosis have official names and clear functions, apart from H19, RNA component of mitochondrial RNA processing endoribonuclease (RMRP), and telomerase RNA component (TERC). A previous study demonstrated that H19 regulates biological processes on at least 3 separate levels of the highest significance: in imprinting, as an lncRNA transcript, and as the miR-675 host (23). Another study showed that it can affect the expression of IGF (24). In the present study, H19 was upregulated, whereas IGF binding protein 11 was downregulated. GO analysis showed that some differentially expressed genes were involved in IGF binding. However, whether H19 has a negative regulatory effect on IGF and the regulatory mechanisms involved in IPF require further verification.

RMRP in rats measures 257 nucleotides in length. Maida *et al* discovered that human telomerase reverse transcriptase (TERT) and RMRP form a distinct ribonucleoprotein complex that has RNA-dependent RNA polymerase activity and produces double-stranded RNAs that can be processed into small interfering RNA in a Dicer (also known as DICER1)-dependent manner (25). TERT mutations have been reported in aplastic anemia and IPF (26). Moreover, the catalytic TERT and TERC are the minimal components of active telomerase (27). TERC not only serves as a template for telomeric DNA synthesis but also plays an important role in catalysis, accumulation, localization and holoenzyme assembly (28-30). Some mutations in TERC can result in a significant change in enzyme activity *in vivo* and *in vitro* (30). Recently, Calado *et al* (31) reported that human telomere disease includes pulmonary fibrosis due to the disruption of the CCAAT box of the TERC promoter, as described by Aalbers *et al* (32). Accordingly, it can be hypothesized that RMRP and TERC are both crucial to the development process of lung fibrosis.

Two more differentially expressed lncRNAs were detected by *in situ* hybridization for paraffin-embedded lung tissue: AJ005396 and S69206. To date, limited studies have applied *in situ* hybridization to measure lncRNA levels in formalin-fixed paraffin-embedded tissue samples. By querying the NCBI database, we found that AJ005396 is an mRNA for collagen $\alpha 1$ type XI (col11a1) and that S69206 is protease mRNA. In addition, the UCSC database revealed that the AJ005396 and S69206 sequences overlapped with col11a1 and rat mast cell protease 1 precursor (RMCP-1), respectively. In the present study, AJ005396 and S69206 were upregulated, but there was no significant change in col11a1 and RMCP-1 between the differentially expressed mRNAs. Although the database displayed that they contained a potential CDS region, it only predicted protein sequences that must be confirmed with further experiments. Thus, ArrayStar regards them as potential lncRNAs. Moreover, previous studies have shown that parts of lncRNAs overlapped with protein-coding gene sequences, such as MVIH [an lncRNA located within the intron of the ribosomal protein S24 (RPS24) gene] (33) and RERT (an lncRNA whose sequence overlaps with Ras-related




Figure 5. Gene Ontology (GO) analysis of functional classification of the target genes. The chart shows the top 10 counts of the significant enrichment terms. (A) Downregulated mRNAs associated with biological processes in model vs. normal group. (B) Downregulated mRNAs associated with cellular components in model vs. normal group. (C) Downregulated mRNAs associated with molecular functions in model vs. normal group. (D) Upregulated mRNAs associated with biological processes in model vs. normal group. (E) Upregulated mRNAs associated with cellular components in model vs. normal group. (F) Upregulated mRNAs associated with molecular functions in model vs. normal group.

GTP-binding protein 4b and EGLN2) (34). Subsequently, they proved using the Open Reading Frame (ORF) Finder and codon substitution frequency analysis that the overexpressed lncRNA, MVIH, in hepatocellular carcinoma (HCC) is a non-coding RNA transcribed independently of the RPS24 gene and that no correlation existed between the transcriptional levels of RPS24 and MVIH (33). Another study showed that the overexpression of the RERT lncRNA upregulated EGLN2 (34). Dharap *et al* found 62 stroke-responsive lncRNAs showing 90% sequence homology with exons of protein-coding genes in their study on lncRNA expression profiles in focal ischemia (35). Similarly, Ziats *et al* reported that most differentially expressed lncRNAs in autism spectrum disorders (ASD) were from intergenic regions (~60%), from antisense to protein-coding loci (~15%), or within introns of protein-coding genes (~10%), with the others representing overlapping transcripts from exons or introns in both sense and antisense directions (36). Another complicating factor is the presence of bifunctional RNAs, which are transcripts that function as non-coding transcripts under certain conditions and are translated into

functional proteins in other situations (37,38). In view of this, in a subsequent study, we hope to confirm whether AJ005396 and S69206 are lncRNAs and transcribed independently of their overlapping protein-coding RNAs and whether an interaction between their expressions exists.

Furthermore, our array contained probes for known protein-coding transcripts and carried out pathway analysis as well as GO analysis based on differentially expressed mRNAs. Before this, numerous studies of the mRNA or miRNA transcriptome in pulmonary fibrosis have been performed. Research has shown that genes related to the immune system, structural constituents of the cytoskeleton, cellular adhesion, metabolism of the ECM, chemokines and tissue remodeling are overexpressed in fibrotic lesions (39,40), which is consistent with our results. Another study focusing on the KEGG pathway to identify fibrosis-associated genes targeted by miRNAs in the late phase after bleomycin infusion, discovered that they mainly involved cytokine-cytokine receptor interaction, focal adhesion and the Jak/STAT signaling pathway (41). Consistent with this article, cytokine-cytokine receptor inter-

action exhibited a similarly significant change in our pathway analysis. In addition, the cell cycle, the renin-angiotensin system, the PPAR signaling pathway, the chemokine signaling pathway, cell adhesion molecules, the Jak/STAT signaling pathway and other signaling pathways were involved in the bleomycin-induced lung fibrosis. Recent studies have indicated that PPAR- γ ligands inhibit TGF β signaling by affecting two pro-survival pathways that culminate in myofibroblast differentiation. Further investigation of PPAR- γ ligands and small electrophilic molecules may lead to a new generation of anti-fibrotic therapeutics (42,43).

In conclusion, the current study used microarray analysis to systematically and comprehensively examine global lncRNA expression in a rat model of bleomycin-induced lung fibrosis and in a normal control group. lncRNA target prediction and further functional characterization may help to elucidate their specific roles in lung injury and fibrosis. The related experiments are currently in progress in our laboratory. Further studies on lncRNA should expand our understanding of the genomic regulatory networks in lung fibrosis and may provide new potential therapeutic targets in lung fibrosis.

Acknowledgements

This study was supported by the 'Taishan scholar' position and the National Natural Science Foundation of China (no. 81273957), the Important Project of Science and Technology of Shandong Province (nos. 2010GWZ20254 and 2011GHY11501), the Natural Science Foundation of Shandong Province (nos. ZR2009EM006 and ZR2012HQ042) and the Project of Science and Technology of the Education Department of Shandong Province (no. J11FL87).

References

1. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). *Am J Respir Crit Care Med* 161: 646-664, 2000.
2. Noble PW and Homer RJ: Back to the future: historical perspective on the pathogenesis of idiopathic pulmonary fibrosis. *Am J Respir Cell Mol Biol* 33: 113-120, 2005.
3. Noble PW and Homer RJ: Idiopathic pulmonary fibrosis: new insights into pathogenesis. *Clin Chest Med* 25: 749-758, 2004.
4. Ding Q, Luckhardt T, Hecker L, *et al*: New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis. *Drugs* 71: 981-1001, 2011.
5. ENCODE Project Consortium, Birney E, Stamatoyannopoulos JA, Dutta A, *et al*: Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. *Nature* 447: 799-816, 2007.
6. Guttman M, Amit I, Garber M, *et al*: Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. *Nature* 458: 223-227, 2009.
7. Nagano T and Fraser P: Emerging similarities in epigenetic gene silencing by long noncoding RNAs. *Mamm Genome* 20: 557-562, 2009.
8. Kim A, Zhao H, Ifrim I and Dean A: Beta-globin intergenic transcription and histone acetylation dependent on an enhancer. *Mol Cell Biol* 27: 2980-2986, 2007.
9. Lee JT: Lessons from X-chromosome inactivation: long ncRNA as guides and tethers to the epigenome. *Genes Dev* 23: 1831-1842, 2009.
10. Rinn JL, Kertesz M, Wang JK, *et al*: Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. *Cell* 129: 1311-1323, 2007.
11. Krangel MS: T cell development: better living through chromatin. *Nat Immunol* 8: 687-694, 2007.
12. Perez DS, Hoage TR, Pritchett JR, *et al*: Long, abundantly expressed non-coding transcripts are altered in cancer. *Hum Mol Genet* 17: 642-655, 2008.
13. Kanehisa M, Goto S, Furumichi M, Tanabe M and Hirakawa M: KEGG for representation and analysis of molecular networks involving diseases and drugs. *Nucleic Acids Res* 38: D355-D360, 2010.
14. Mattick JS and Makunin IV: Non-coding RNA. *Hum Mol Genet* 15: R17-R29, 2006.
15. Mattick JS: The genetic signatures of noncoding RNAs. *PLoS Genet* 5: e1000459, 2009.
16. Wang KC and Chang HY: Molecular mechanisms of long noncoding RNAs. *Mol Cell* 43: 904-914, 2011.
17. Hindorf LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS and Manolio TA: Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. *Proc Natl Acad Sci USA* 106: 9362-9367, 2009.
18. Lin R, Maeda S, Liu C, Karin M and Edgington TS: A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. *Oncogene* 26: 851-858, 2007.
19. Qureshi IA, Mattick JS and Mehler MF: Long non-coding RNAs in nervous system function and disease. *Brain Res* 1338: 20-35, 2010.
20. Tufarelli C, Stanley JA, Garrick D, Sharpe JA, Ayyub H, Wood WG and Higgs DR: Transcription of antisense RNA leading to gene silencing and methylation as a novel cause of human genetic disease. *Nat Genet* 34: 157-165, 2003.
21. Wapinski O and Chang HY: Long noncoding RNAs and human disease. *Trends Cell Biol* 21: 354-361, 2011.
22. Sui W, Yan Q, Li H, Liu J, Chen J, Li L and Dai Y: Genome-wide analysis of long noncoding RNA expression in peripheral blood mononuclear cells of uremia patients. *J Nephrol*: Oct 24, 2012 (Epub ahead of print).
23. Steck E, Boeuf S, Gabler J, Werth N, Schnatzer P, Diederichs S and Richter W: Regulation of H19 and its encoded microRNA-675 in osteoarthritis and under anabolic and catabolic in vitro conditions. *J Mol Med (Berl)* 90: 1185-1195, 2012.
24. Tran VG, Court F, Duputié A, Antoine E, *et al*: H19 antisense RNA can up-regulate Igf2 transcription by activation of a novel promoter in mouse myoblasts. *PLoS One* 7: e37923, 2012.
25. Maida Y, Yasukawa M, Furuuchi M, *et al*: An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. *Nature* 461: 230-235, 2009.
26. Calado RT and Young NS: Telomere maintenance and human bone marrow failure. *Blood* 111: 4446-4455, 2008.
27. Weinrich SL, Pruzan R, Ma L, *et al*: Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTERT. *Nat Genet* 17: 498-502, 1997.
28. Zhang Q, Kim NK and Feigon J: Architecture of human telomerase RNA. *Proc Natl Acad Sci USA* 108: 20325-20332, 2011.
29. Cong Y and Shay JW: Actions of human telomerase beyond telomeres. *Cell Res* 18: 725-732, 2008.
30. Zvereva MI, Shcherbakova DM and Dontsova OA: Telomerase: structure, functions, and activity regulation. *Biochemistry (Mosc)* 75: 1563-1583, 2010.
31. Calado RT and Young NS: Telomere diseases. *N Engl J Med* 361: 2353-2365, 2009.
32. Aalbers AM, Kajigaya S, van den Heuvel-Eibrink MM, van der Velden VH, Calado RT and Young NS: Human telomere disease due to disruption of the CCAAT box of the TERC promoter. *Blood* 119: 3060-3063, 2012.
33. Yuan SX, Yang F, Yang Y, *et al*: Long noncoding RNA associated with microvascular invasion in hepatocellular carcinoma promotes angiogenesis and serves as a predictor for hepatocellular carcinoma patients' poor recurrence-free survival after hepatectomy. *Hepatology* 56: 2231-2241, 2012.
34. Zhu Z, Gao X, He Y, *et al*: An insertion/deletion polymorphism within RERT-lncRNA modulates hepatocellular carcinoma risk. *Cancer Res* 72: 6163-6172, 2012.
35. Dharap A, Nakka VP and Vemuganti R: Effect of focal ischemia on long noncoding RNAs. *Stroke* 43: 2800-2802, 2012.
36. Ziats MN and Rennert OM: Aberrant expression of long noncoding RNAs in autistic brain. *J Mol Neurosci* 49: 589-593, 2012.
37. Dinger ME, Pang KC, Mercer TR and Mattick JS: Differentiating protein-coding and noncoding RNA: challenges and ambiguities. *PLoS Comput Biol* 4: e1000176, 2008.
38. Ulveling D, Francastel C and Hube F: When one is better than two: RNA with dual functions. *Biochimie* 93: 633-644, 2011.

39. Hanaoka M, Ito M, Droma Y, Ushiki A, Kitaguchi Y, Yasuo M and Kubo K: Comparison of gene expression profiling between lung fibrotic and emphysematous tissues sampled from patients with combined pulmonary fibrosis and emphysema. *Fibrogenesis Tissue Repair* 5: 17, 2012.
40. Konishi K, Gibson KF, Lindell KO, *et al*: Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 180: 167-175, 2009.
41. Xie T, Liang J, Guo R, Liu N, Noble PW and Jiang D: Comprehensive microRNA analysis in bleomycin-induced pulmonary fibrosis identifies multiple sites of molecular regulation. *Physiol Genomics* 43: 479-487, 2011.
42. Kulkarni AA, Thatcher TH, Olsen KC, Maggirwar SB, Phipps RP and Sime PJ: PPAR- γ ligands repress TGF β -induced myofibroblast differentiation by targeting the PI3K/Akt pathway: implications for therapy of fibrosis. *PLoS One* 6: e15909, 2011.
43. Ferguson HE, Kulkarni A, Lehmann GM, *et al*: Electrophilic peroxisome proliferator-activated receptor- γ ligands have potent antifibrotic effects in human lung fibroblasts. *Am J Respir Cell Mol Biol* 41: 722-730, 2009.